UNSPSC 51171853: Tropisetron

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6I819NIK1W, chemically known as 1h-indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo- but generally known as tropisetron, which bears US NIH Compound Identifier 72165. European Medicines Agency schedules Tropisetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11345MIG.

UNSPSC 51171853 Tropisetron is a Commodity code that frames a single pharmaceutical product line, but the recent state and local procurement activity tagged under it spans drug testing services, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceutical distribution — a mismatch between the code's nominal scope and the work actually being solicited. The issuing bodies include county criminal-justice agencies, state health and human services departments, and multistate cooperative purchasing alliances. The work encompasses specimen collection and drug-testing operations (staffing, lab certification, immunoassay and confirmatory analysis), exploratory procurement for direct manufacturer-to-plan prescription programs, and competitive bidding for generic pharmaceutical and OTC product distribution through authorized wholesalers.

Recent activity shows geographic spread across Texas (Collin County and the Texas Health and Human Services Commission) and Minnesota (MMCAP, which serves multiple states including Oregon). Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, due July 23, 2026, seeking offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, with up to three optional one-year renewals; evaluation will weight vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional demonstrations and interviews (up to 30 points). The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026, due April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, for multi-source generic pharmaceuticals and OTC products to be distributed through three authorized wholesalers, with awards effective July 1, 2026, evaluated primarily on price competitiveness (75 percent) and secondarily on pricing structures, administrative compliance, EDI capability, and administrative fee acceptance (25 percent combined).